Sociedad Americana de Hirudoterapia

Textbook outcomes in DIEP flap breast reconstruction: a Delphi study to establish consensus.

Research article published in Breast cancer research and treatment (2022)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosShammas et al. · Breast cancer research and treatment, 2022

Abstract

PURPOSE: Composite measures, like textbook outcomes, may be superior to individual metrics when assessing hospital performance and quality of care. This study utilized a Delphi process to define a textbook outcome in DIEP flap breast reconstruction. METHODS: A two-round Delphi survey defined: (1) A textbook outcome, (2) Exclusion criteria for a study population, and (3) Respondent opinion regarding textbook outcomes. An a priori threshold of ≥ 70% agreement among respondents established consensus among the tested statements. RESULTS: Out of 85 invitees, 48 responded in the first round and 41 in the second. A textbook outcome was defined as one that meets the following within 90 days: (1) No intraoperative complications, (2) Operative duration ≤ 12 h for bilateral and ≤ 10 h for unilateral/stacked reconstruction, (3) No post-surgical complications requiring re-operation, (4) No surgical site infection requiring IV antibiotics, (5) No readmission, (6) No mortality, (7) No systemic complications, and (8) Length of stay < 5 days. Exclusion criteria for medical and surgical characteristics (e.g., BMI > 40, HgbA1c > 7) and case-volume cut-offs for providers (≥ 21) and institutions (≥ 44) were defined. Most agreed that textbook outcomes should be defined for complex plastic surgery procedures (75%) and utilized to gauge hospital performance for microsurgical breast reconstruction (77%). CONCLUSION: This Delphi study identified (1) Key elements of a textbook outcome for DIEP flap breast reconstruction, (2) Exclusion criteria for future studies, and (3) Characterized surgeon opinions regarding the utility of textbook outcomes in serving as quality metric for breast reconstruction care.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansFemaleMastectomyConsensusDelphi TechniquePerforator FlapBreast NeoplasmsMammaplastyRetrospective StudiesPostoperative ComplicationsTreatment Outcome

Resumen

Composite measures, like textbook outcomes, may be superior to individual metrics when assessing hospital performance and quality of care. This study utilized a Delphi process to define a textbook outcome in DIEP flap breast reconstruction.

Por qué esto importa para la hirudoterapia

This Delphi study established a consensus definition for a "textbook outcome" in DIEP flap breast reconstruction, encompassing criteria such as no intraoperative complications, no surgical site infections, and no post-surgical complications requiring re-operation. The study defines quality metrics and exclusion criteria for assessing hospital performance and surgical success in complex microsurgical breast procedures. The abstract focuses exclusively on these surgical benchmark definitions and does not mention specific postoperative flap complications, venous congestion, or salvage therapies. Consequently, the article does not reference leeches, hirudotherapy, or the leech secretome, making its relevance to the American Society of Hirudotherapy entirely lacking.

Citación

Textbook outcomes in DIEP flap breast reconstruction: a Delphi study to establish consensus.

Shammas et al. · Breast cancer research and treatment, 2022

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.